Investors are closely watching Eli Lilly & Company (LLY) as the pharmaceutical giant prepares to release its fiscal third-quarter results later this week. Experts are predicting strong performance driven by the strong demand of Lilly's blockbuster treatments, particularly the diabetes franchise. However, there are also concerns about potential head… Read More